« Shortage of Blogification |
| The Ultimate in Personalized Medicine »
March 23, 2012
Longtime readers will remember the interaction I had with Nativis Pharmaceuticals. That's the outfit that claims to be working with "drug signatures" instead of the drug molecules themselves. I found it interesting to see a company with all the outward trappings of a biotech startup that was spending its time (and its investors' money) on what sounded to me like the next thing to homeopathy. "Unique photon fields" of drug molecules? "Photon payloads" from "imprinted coherence domains"? You don't run across this sort of thing every day - well, not where I work.
When I said so, though, I got to hear from the company's chief legal counsel, and we ended up trading helpful advice. (Well, I thought my advice to him was helpful, at any rate). We have not crossed paths since.
But readers are reporting that the company's San Diego site appears to be emptied out, so I decided to check up on them. As it happens, they do not seem to be out of business: they're just moving to Seattle. Now, why the company seems to have pulled back its presence on its own web site, and on LinkedIn, etc., I don't know. And whatever happened to the publications that they were planning, and to their IND, I don't know, either. But at least as of last fall, they were a going concern. If any readers up the Northwest hear some news, please pass it on!
+ TrackBacks (0) | Category: Snake Oil
POST A COMMENT
- RELATED ENTRIES
- A Last Summer Day Off
- The Early FDA
- Drug Repurposing
- The Smallest Drugs
- Life Is Too Short For Some Journal Feeds
- A New Look at Phenotypic Screening
- Small Molecules - Really, Really Small
- InterMune Bought